Galante Laura, Pundir Shikha, Lagström Hanna, Rautava Samuli, Reynolds Clare Marie, Milan Amber Marie, Cameron-Smith David, Vickers Mark Hedley
The Liggins Institute, University of Auckland, Auckland, New Zealand.
Department of Public Health, University of Turku and Turku University Hospital, Turku, Finland.
Front Nutr. 2020 Jul 29;7:110. doi: 10.3389/fnut.2020.00110. eCollection 2020.
Human milk bioactives may play a role in infant health and development. Although the variability in their concentrations in milk is well-established, the impact of differential milk profiles on infant growth outcomes remains unclear. Thus, the aim of the present study was to investigate whether different concentrations of metabolic hormones are associated with different weight and BMI in infants beyond the first year of life. Milk samples at 2.6 (±0.4) months after birth and anthropometric measures at 13 months, 2, 3, and 5 years were collected as part of the Finnish STEPS cohort study from 501 mothers and the respective 507 infants. Leptin, adiponectin, insulin-like growth factor (IGF)-1 and cyclic glycine-proline (cGP) in milk were analyzed. Multiple regression models and a repeated measures mixed model were used to examine associations between milk hormone concentrations and weight and BMI z-scores across time, at each time-point, and weight gain from birth to each follow-up visit. All models were corrected for birth weight, infant sex, duration of exclusive and total breastfeeding, time of introduction of solid foods and maternal pre-pregnancy BMI. Higher milk IGF-1 was associated with higher weight at 13 months ( = 0.004) but lower weight at 3 ( = 0.011) and 5 years of age ( = 0.049). Higher cGP was associated with lower weight across the 5 years ( = 0.019) but with higher BMI at 5 years ( = 0.021). Leptin and adiponectin did not display associations with infant growth at this time. Sex interactions were also absent. Our results suggest that the interplay between human milk-borne IGF-1 and cGP is similar to that reported in other mammals and may have an important role in defining infant growth trajectories beyond the first year of life. Further research should explore the determinants and origins of these milk-borne compounds and evaluate their effect on infant growth and metabolism.
母乳中的生物活性物质可能对婴儿的健康和发育发挥作用。尽管母乳中这些物质的浓度存在差异已得到充分证实,但不同的母乳成分对婴儿生长结果的影响仍不明确。因此,本研究的目的是调查生命第一年之后,不同浓度的代谢激素是否与婴儿不同的体重和体重指数(BMI)相关。作为芬兰STEPS队列研究的一部分,收集了501名母亲及其相应507名婴儿出生后2.6(±0.4)个月时的母乳样本以及13个月、2岁、3岁和5岁时的人体测量数据。分析了母乳中的瘦素、脂联素、胰岛素样生长因子(IGF)-1和环甘氨酰脯氨酸(cGP)。采用多元回归模型和重复测量混合模型,来检验母乳激素浓度与不同时间点的体重和BMI z评分之间的关联,以及从出生到每次随访的体重增加情况。所有模型均对出生体重、婴儿性别、纯母乳喂养和全母乳喂养的持续时间、固体食物引入时间以及母亲孕前BMI进行了校正。较高的母乳IGF-1与13个月时较高的体重相关(P = 0.004),但与3岁(P = 0.011)和5岁时较低的体重相关(P = 0.049)。较高的cGP与5年期间较低的体重相关(P = 0.019),但与5岁时较高的BMI相关(P = 0.021)。此时,瘦素和脂联素与婴儿生长无关联。也不存在性别交互作用。我们的结果表明,母乳中IGF-1和cGP之间的相互作用与其他哺乳动物的情况相似,可能在确定生命第一年之后的婴儿生长轨迹中发挥重要作用。进一步的研究应探索这些母乳中化合物的决定因素和来源,并评估它们对婴儿生长和代谢的影响。